

Contact:

Jeff Misakian, Valeant Pharmaceuticals
949-461-6184

**VALEANT PHARMACEUTICALS BEGINS DISTRIBUTION OF [◇]XYREM[®] IN
CANADA**

- Special Success Program Initiated for Patients with Cataplexy -

ALISO VIEJO, Calif., July 30, 2007 - Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has launched the Xyrem Success Program™ for [®]Xyrem[®] (sodium oxybate), the first and only product approved in Canada to treat cataplexy, a sudden loss of muscle tone associated with narcolepsy. Valeant will distribute Xyrem in Canada through its specialty sales force and will be promoted exclusively to neurologists, psychiatrists, pulmonologists, and sleep specialists who treat patients with narcolepsy.

“The Xyrem Success Program is the latest example of our efforts to provide the best care and support for patients,” said Wesley P. Wheeler, president, North America and Research and Development. “Valeant is committed to advancing the care of people living with cataplexy and narcolepsy.”

The Xyrem Success Program in Canada is staffed by trained registered nurses who provide information and direction on specific disease and drug-related issues. They also verify training and education for physicians, pharmacists, and patients in Canada and are responsible for compiling the required patient information. The program is also assisted by trained support staff who are responsible for the administrative aspects of the program. The registered nurses and trained support staff of the program are accessible via a toll free support line available to physicians, healthcare professionals, and patients enrolled in the program. Xyrem will be distributed through a central pharmacy that is connected with the Xyrem Success Program.

Xyrem has demonstrated an acceptable safety profile in narcoleptics with cataplexy when administered in nightly divided doses of 6 to 9 g with a recommended starting dose of 4.5 g/night. The adverse event profile was generally consistent with the known pharmacological actions of sodium oxybate and intercurrent disease states. The most commonly reported adverse drug reactions are dizziness, nausea, and headache, occurring in 17-25 percent of patients. These are not the only possible effects with Xyrem. Patients administered Xyrem should be monitored for treatment-emergent adverse events. Physicians and patients can obtain additional prescribing information regarding Xyrem, including the product’s safety profile and the box warning by contacting Valeant Canada at 1-800-361-4261.

-more-

About Cataplexy

Cataplexy is a sudden loss of muscle tone that is a debilitating symptom of narcolepsy. Cataplexy may occur more frequently during times of stress or fatigue. The cataplectic attack may involve only a slight feeling of weakness and limp muscles (i.e., sagging facial muscles, a nodding head, buckling knees, loss of arm strength, garbled speech), or it may result in immediate and total body collapse, during which the person may appear unconscious, but is actually awake and alert. These attacks may last from a few seconds up to several minutes. Cataplectic episodes are related to the loss of muscle tone usually associated with the normal dreaming stage of sleep called rapid eye movement (REM); as a protection against acting out one's dreams, the muscles become immobile or paralyzed.

About Narcolepsy

Narcolepsy is a complex, lifelong neurological disease characterized by fragmented nighttime sleep, excessive daytime somnolence (EDS), cataplexy, sleep paralysis, and hypnagogic hallucinations. At various times throughout the day, people with narcolepsy experience fleeting urges of sleep. If the urge is overwhelming, individuals will fall asleep for periods lasting from a few seconds to several minutes. In addition to excessive daytime sleepiness, three other major symptoms frequently characterize narcolepsy: cataplexy or the sudden loss of voluntary muscle tone; vivid hallucinations during sleep onset or upon waking; and brief episodes of total paralysis at the beginning or end of sleep. The cause of narcolepsy is unknown and likely involves multiple interacting factors that causes neurological dysfunction and sleep disturbances.

About Valeant:

Valeant Pharmaceuticals International (NYSE:VRX) is a global specialty pharmaceutical company that develops, manufactures and markets products primarily in the areas of neurology, infectious disease and dermatology. More information about Valeant can be found at www.valeant.com.

###